**Role of Non-coding RNAs in Cystic Fibrosis**

Jessica Varilh, Jennifer Bonini and Magali Taulan-Cadars

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/60449

#### **Abstract**

sis patients carrying stop mutations. Am J Respir Crit Care Med. 2000;161(3 Pt 1):

[150] Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539-47.

[151] Amaral MD, Farinha CM. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharmaceut Design. 2013;19(19):3497-508.

[152] Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med.

[153] Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised

[154] Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibro‐

[155] Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros. 2015 Mar 11. pii:

[156] Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat

[157] Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros. 2006;5(1):17-25.

[158] Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, et al. Pro‐ found functional and signaling changes in viable inflammatory neutrophils homing

[159] Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit

[160] Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, et al. Activation of criti‐ cal, host-induced, metabolic and stress pathways marks neutrophil entry into cystic

[161] Laval J, Touhami J, Herzenberg LA, Conrad C, Taylor N, Battini JL, et al. Metabolic adaptation of neutrophils in cystic fibrosis airways involves distinct shifts in nutrient

to cystic fibrosis airways. Proc Natl Acad Sci USA. 2008;105(11):4335-9.

fibrosis lungs. Proc Natl Acad Sci USA. 2009;106(14):5779-83.

transporter expression. J Immunol. 2013;190(12):6043-50.

sis: promises, progress, pitfalls. Pharmacol Therapeut. 2015;145:19-34.

controlled trial. Lancet Respir Med. 2014;2(7):527-38.

860-5.

278 Cystic Fibrosis in the Light of New Research

2011;365(18):1663-72.

S1569-1993(15)00050-8.

Med. 2007;13(12):1423-30.

Care Med. 1995;152(6 Pt 1):1910-6.

Cystic Fibrosis (CF) is a common autosomal recessive disorder, caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (*CFTR*) gene. *CFTR* gene expression is tightly controlled by transcriptional and post-transcriptional regulatory factors, resulting in complex spatial and temporal expression patterns. Here, we describe an overview of the findings about the contribution of ncRNAs, especially miRNAs, in physiological *CFTR* gene expression and in CF. Determination of mechanisms governing its expression is essential for developing new CF therapies. ncRNAs, including lncRNAs and miRNAs, could also contribute to CF progression and severity and their dysregulation in CF opens new perspectives for patient followup and treatment.

**Keywords:** CFTR gene expression, Cystic Fibrosis, non-coding RNA, lncRNA, miR‐ NA
